

METASTAT RGCC™

Results



Results Analysis Report on a patient Mr John Doe suffering from Prostate malignancy, stage II.



The sample that was sent to us for analysis was a sample of 20ml Blood that contains anti-coagulant, and packed with an ice pack.

Laboratory Process

1. CTCs are isolation from whole blood through negative selection.
2. mRNA isolation using TRIzol reagent.
3. cDNA synthesis from mRNA with First strand cDNA synthesis kit.
4. Specific gene markers were quantified with Real Time PCR assay.
5. Flow cytometry run for the specific markers directly to whole blood.

The data arising from the two assays were then analyzed and compared to the normal ones.
During the test the environmental temperature was: $23^{\circ}\text{C} \pm 1^{\circ}\text{C}$.

METASTASIS LOCATION	MARKER	SAMPLE LEVELS	NORMAL LEVELS	RESULTS
General	TGF-b R2	7.27	7.27	-
	ITGB-4 R	15	7.98	-
	ITGB-5 R	10.05	11.11	UP REGULATED
	ITGB-6 R	15	11.59	-
Pleura	CCR6	9.58	9.58	-
	Mesothelin	15	10.36	-
Skin	CCR7	15	6.78	-
Lung	IGF-R2	9.65	9.65	-
	Phospho-ERK1	15	11.07	-
	Phospho-ERK2	8.14	9.44	UP REGULATED
Bone	BMPR 1a	15	11.66	-
	BMPR 1b	10.62	12.25	UP REGULATED
	BMPR 2	15	11.58	-
	CXCR4	15	9.51	-
	RANK	15	13.49	-
	BST-2	5.87	5.87	-

METASTASIS LOCATION	MARKER	SAMPLE LEVELS	NORMAL LEVELS	RESULTS
Liver	CXCR4	15	9.51	-
	TRAIL-R2	15	9.03	-
	FAS R	15	9.18	-
	HGFR	8.75	8.75	-
Brain	Phospho-STAT-3	15	7.30	-
	CX3CR1	15	5.93	-
	DSC-2	11.96	11.96	-

Two methods were used in order to increase the accuracy of the results. Flow cytometry was carried out with the use of the above specific antibodies and Real Time PCR was held using primers designed to recognize specifically the genes of these proteins.

Genes in up regulation are ITGB-5 R, Phosho-ERK2, BMPR 1b

According to the results, there is a major trend of metastasis of the primary tumor mainly towards the Lung, Bone

Modification of data, selective breeding and using portions of this test report is forbidden. The laboratory assumes no liability for improper use or improper interpretation of the results.

Ioannis Papatiriu MD., PhD Head of molecular medicine dpt. of R.G.C.C.-Research Genetic Cancer Centre International GmbH